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Openness and transparency are important considerations for medicines regulators, where public health
is of paramount concern. As part of their commitment to transparency, the European Medicines Agency
(EMA) and Therapeutic Goods Administration (TGA) in Australia publish information relating to their
evaluation of medicines via public assessment reports. European Public Assessment Reports (EPARs) and
Australian Public Assessment Reports (AusPARs) provide information about the considerations that led
the regulator to approve or refuse the application. The reports summarise assessments by each regulator
of the information provided on the quality, safety, and efficacy of the medicine under evaluation. Here,
we describe the experiences of two established medicines regulators in publishing public assessment
reports, and reflect on their future role in communicating medicines information.Introduction
The TGA and EMA contribute to the protection and promotion of
public health as regulatory bodies responsible for evaluating new
medicines for human use in Australia and the European Union
(EU), respectively. Openness and transparency are important
means by which a regulator seeks to provide the public with
confidence in its processes [1]. As part of their commitment to
transparency, both regulators publish information on their respec-
tive websites (EMA: www.ema.europa.eu; TGA: www.tga.gov.au)
about their decisions relating to medicines evaluations [2,3]. EMA
publishes EPARs and TGA publishes AusPARs. Each public assess-
ment report outlines the outcomes of the evaluation process of
the regulator and provides a record of the scientific reasoning on
which a decision was made to approve or refuse an application
for marketing authorisation. Here, we discuss the rationale
and approach for publishing EPARs and AusPARs over time and
reflect on their future role in communicating information about
medicines.Corresponding authors:. Papathanasiou, P. (peter.papathanasiou@gmail.com),
Kieffer, J. (jill.kieffer@ema.europa.eu)
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In 1995, the publication of EPARs was a significant pioneering step
for a regulatory body and constituted an important milestone in
building a regulatory network involving national competent au-
thorities for medicines in 31 European countries. This move was in
line with the commitment to public disclosure built into EMA
from its inception [4]. In a similar way, the first AusPAR was
published in 2009 as part of the commitment of the TGA to the
increased transparency strategy of the Australian Government.
EPARs
Following the establishment of the European medicines system in
1995 with an explicit commitment to transparency [5], EPARs were
founded on Article 12 of Regulation (EEC) No. 2309/93. This legisla-
tion required the agency to make the reasons for granting authori-
sation available on request. The EMA went beyond this requirement
and began publishing EPARs from the very first centrally authorised
product in 1995. Although critics did not believe a change to greater
transparency was possible because of concerns about safeguarding
commercially sensitive information [6], industry gradually accepted
the principles of the EPAR. The first EPARs comprise the assessment
report and approved product information (PI).pen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.drudis.2016.06.025
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changes. However, because of challenges in document layout and
readability, this information on postmarketing changes was pub-
lished separately from 1999 onwards. In 2004, EPAR publication
was enacted into Regulation (EC) No. 726/2004, which also intro-
duced the requirement for publication of a summary for the
public. These requirements recognised the need to present infor-
mation in publicly accessible language [7]. This legislation also
required publication of assessment reports for those medicines
when applications for marketing authorisation were withdrawn or200(a)
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FIG. 1
Number of public assessment reports published annually to 2015. (a) European Pub
indicate extension of indication updates. (b) Australian Public Assessment Reportrefused. The EPARs of centrally authorised medicines are now
updated to incorporate new data throughout the life of the medi-
cine and are available on the EMA website via a dedicated page for
each medicine. To the end of 2015, 1179 EPARs for individual
human medicines had been published along with 565 EPAR
updates for extensions of indications (Fig. 1a).
AusPARs
The first AusPAR was published on 13 November 2009 as part of
the implementation by the TGA of an increased transparency 2005
Year
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lic Assessment Reports (EPARs) published annually from 1995. ‘EPAR updates’
s (AusPARs) published annually from 2009.
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icines. An amendment of legislative provisions followed [Section
61 of the Therapeutic Goods Act 1989 (Cth)].
AusPARs are published for prescription medicine applications
considered for entry, or variation of entry, into the Australian
Register of Therapeutic Goods (ARTG); these therapeutic goods
can then be lawfully supplied in Australia [8]. AusPARs are gener-
ally only prepared for applications where TGA has sought advice
from its Advisory Committee on Prescription Medicines (ACPM)
before a decision and includes all applications relating to new
chemical and biological entities and extensions of indications
(Table S1 in the supplementary data). Compared with the EPAR,
each AusPAR represents the evaluation and decision-making
process for a single application, rather than a compilation of
decisions for a single medicine. To the end of 2015, a total of
445 AusPARs had been published for 378 individual prescription
medicines (Fig. 1b). The majority were for new drug entities
(chemical or biological) (n = 179; 35.4%) and extensions of indi-
cations (n = 175; 34.7% of total AusPARs) (Figure S1 in the sup-
plementary data), with most for approved applications (n = 407;
91%), 5% (n = 22) for withdrawn, and 4% (n = 16) for rejected
applications.
Content of EPARs and AusPARs
EPARs
The website of the EMA provides, in a single location for each
product, a folio of information comprising: (i) the assessment
report produced by the original evaluation of the Committee plus
further reports for each major change to the marketing authorisa-
tion; (ii) the updated PI, comprising the most current version of
the Summary of Product Characteristics (SmPC), which is aimed at
healthcare professionals, plus the package leaflet for patients and
the labelling of the medicine; (iii) a public-friendly and regularly
updated summary in a Question and Answer format (EPAR sum-
mary); and (iv) a history of procedural changes made to the
marketing authorisation (Table S2 in the supplementary data).
The PI and EPAR summary are translated into 25 European
languages to serve the multilingual environment of the EU. The
PI provides the necessary information for both healthcare profes-
sionals and patients on how to use the medicine safely and
effectively. Assessment reports provide detailed medical and sci-
entific information; these are now often over 100 pages and are
published in English only.
AusPARs
Each AusPAR webpage contains three documents: (i) the AusPAR
itself; (ii) the Extract from the Clinical Evaluation Report (CER),
published as a separate attachment; and (iii) for approved applica-
tions, the PI approved with the application, also published as an
attachment.
AusPARs incorporate assessment summaries of the quality,
safety, and efficacy of the medicine using reports prepared as part
of the evaluation and decision-making process of the TGA. The
Extract from the CER is the clinical evaluator’s report presented in
full other than deletions of commercially confidential clinical
information as justified by the sponsor. The publication of the
Extract from the CERs began in July 2013; before this, clinical
information was included in the AusPAR itself. This change was1808 www.drugdiscoverytoday.comimplemented to make the AusPAR more concise and focus its
content on the decision process. Currently, the average AusPAR
length is 70–90 pages; readers seeking more detailed clinical data
are able to access the CER Extract document. AusPARs are pub-
lished in English only.
Content and structure of assessment reports
Assessment reports have the same basic format (Table 1), and the
structure of AusPARs was modelled on that of EPARs. Their struc-
ture and content mirror the legal requirements contained in the
standards and protocols for the development of new medicines [9],
and follow the internationally agreed format [10], in which appli-
cants are required to submit these data when applying for a
marketing authorisation.
In each public assessment report, the main findings of tests and
studies are presented after describing their methodologies. Results
are discussed in the light of compliance with guidelines on the
development of medicines [11] and with principles of good
manufacturing practice (GMP), good clinical practice (GCP), good
laboratory practice (GLP), and good pharmacovigilance practice
(GVP). Clinical data supporting the marketing authorisation are
presented and discussed in depth. The main studies are described
in accordance with the general principles of the CONsolidated
Standards of Reporting Trials (CONSORT) 2010 statement on the
transparent reporting of clinical trials [12]. Clinical safety infor-
mation is concluded with a summary of important identified or
potential risks, missing information, proposed pharmacovigilance
activities, and related risk minimisation measures. Throughout the
assessment report, attention is paid to ensure that information in
the PI optimises the benefits and manages the risks of each medi-
cine.
The assessment report concludes with the recommendation for
marketing authorisation (or not) after a transparent, objective, and
explicit description of the benefit–risk balance. For example, the
benefit–risk balance is described after presenting the beneficial
effects, the unfavourable effects, and their related uncertainties.
Assessment reports also include any views or recommendations
following consultation with a scientific advisory group or ad hoc
expert group. If a sponsor appeals a decision, the re-examination
assessment is also incorporated into the report. In the EU, the final
report is adopted by the Committee for Medicinal Products for
Human Use (CHMP) before redaction for publication. When an
opinion on an authorisation has not been granted consensually,
the divergent positions expressed by Committee members are
appended to the assessment report. This additional information
provides in-depth transparency on the entire decision-making
process.
Commercially confidential information is redacted where the
sponsor can justify deletion. Redaction is in accordance with
principles for the deletion of commercially confidential informa-
tion and the regulators’ policies on transparency [13,14]. Nonclin-
ical and clinical information, together with the accompanying
evaluation, are generally not considered confidential. By contrast,
detailed manufacturing information is usually regarded as com-
mercially sensitive. Figures S2 and S3 in the supplementary data
show how TGA applies these principles and classifies commercially
confidential information. The final decision concerning AusPAR
and EPAR content rests with TGA and EMA, respectively.
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TABLE 1
Content of assessment reportsa
Part Components
1. Background information a. Basic information about the product, extracted from the submission
2. Scientific discussion a. Introduction
i. Problem statement about the product and its development in relation to the disease for
which an indication is claimed
b. Quality aspects
i. Active substance
ii. Finished medicinal product
iii. Summary of the chemical, pharmaceutical, and biological aspects
c. Nonclinical aspects
i. Pharmacology
ii. Pharmacokinetics
iii. Toxicology
iv. Ecotoxicity/environmental risk assessment
v. Summary of the nonclinical aspects
d. Clinical aspects
i. Pharmacokinetics
ii. Pharmacodynamics
iii. Summary of clinical pharmacology
e. Clinical efficacy
i. Dose response studies
ii. Main studies (Phase III; therapeutic confirmatory trials)
iii. Summary of clinical efficacy
f. Clinical safety
i. Patient exposure, adverse events (AEs), serious adverse events (SAEs), laboratory findings
ii. Safety in special populations
iii. Summary of clinical safety
g. Pharmacovigilance system
h. Risk management plan (RMP)
3. Benefit-risk balance a. Assessment of benefits
b. Assessment of risks
c. Assessment of benefit–risk balance
4. Recommendations and conclusion a. Overview of the salient issues identified during the evaluation
b. Decision, including rationale
a AusPARs also include the sponsor’s response to the salient issues included in the Overview section (4a). Similarly, the applicant’s response to CHMP questions are also included in the
assessment report for an EPAR, and are integrated in the most relevant part described above.
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Publication of EPARs and AusPARs on the regulators’ websites
provides access for a broad audience. Here, we discuss the major
categories of stakeholders.
Pharmaceutical industry
The pharmaceutical industry represents an important audience of
medicines regulatory websites. A 2011 EMA web survey indicated
that 65% of responders were from industry; similarly, a 2016 TGA
web survey showed 67% of responders were from industry. A 2008
EMA web survey showed that 75% of web users rated the EPAR as
good or very good. In 2011, an independent Australian survey of
20 companies found that 75% of respondents rated their satisfac-
tion with AusPARs as ‘medium’, with 15% saying it was ‘high’ [15].
The same survey reported that industry believes that AusPARs are
used as a source of competitive information. Greater transparency
might also assist industry by making the regulatory process clearer
and more predictable.
Other health authorities
In the EU, Health Technology Assessment (HTA) bodies have
expressed interest in EPARs. These bodies assess the relativeeffectiveness of medicines to make judgements concerning their
usefulness to the healthcare system in their jurisdiction or to
support decision-making on price and reimbursement. In 2008,
EMA and the European network for HTA (EUnetHTA) initiated a
partnership with the aim that EPARs will further contribute to
assessments of relative effectiveness. As a result, the template of
the European assessment report was revised in 2010 to include a
standardised tabular overview of the main efficacy data from the
pivotal studies, along with additional guidance for discussing
critical aspects of study design, such as endpoints and compara-
tors, or considerations on subgroup analysis [16].
The publication of EPARs also supports the work of the EMA
with health authorities outside the EU. This includes the provision
of certificates to confirm the marketing authorisation status of
medicines submitted through the centralised procedure. In coop-
eration with the World Health Organization (WHO), the EMA
provides scientific opinions on medicinal products intended ex-
clusively for markets outside the EU (Article 58 of Regulation 726/
2004/EC); EPARs are also produced for these scientific opinions.
Healthcare professionals and patients
From the beginning, EMA has interacted with healthcare profes-
sionals and patients, with their involvement growing over timewww.drugdiscoverytoday.com 1809
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sionals [18] stressed that the SmPC is the reference document on
the safe and effective use of a medicine, with the EPAR substanti-
ating this information by describing the benefit–risk balance of
each medicine and informing about risk management activities.
EMA regularly consults patient representatives in the preparation
of EPAR summaries and package leaflets.
TGA provides access to the Consumer Medicines Information
(CMI) document for each medicine on its website. This document
is written by the pharmaceutical company and contains informa-
tion on the safe and effective use of a medicine in lay terminology.
AusPARs are already shared with editors of drug bulletins
through National Prescribing Service (NPS) MedicineWise, a non-
profit organisation providing medicines information through Aus-
tralian Prescriber [19]. This facilitates the timely dissemination of
important medicines information to the public. Drug bulletins
have also communicated interest in EPARs. Today, public assess-
ment reports are shared through the social media platform Twitter
(@TGAgovau; @EMA_News) to further expedite the sharing of
medicine information with patients.
Web traffic
TGA web trends indicate a steady annual rise in visits to AusPAR
pages: from 0.74% in 2010 to 11.47% in 2014, a 15-fold increase in
5 years (Fig. 2). EMA monitoring shows that EPAR webpages are the8 000 000
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FIG. 2
Overall Australian Public Assessment Reports (AusPARs) web traffic 2010–2014.
1810 www.drugdiscoverytoday.commost viewed pages on the EMA website. In November 2014, visits
to EPAR pages represented 8.90% of total EMA website traffic
(Table S3A in the supplementary data); this had increased to
10.36% in September 2015 (Table S3B in the supplementary data).
The AusPAR remains the most viewed document online, out-
performing Extract CER and PI documents overall (Fig. 3). Extract
CER documents had a relatively low proportion of views following
their separation from the AusPAR document in July 2013, al-
though the numbers have slowly increased over time (Figure S4
in the supplementary data). The average number of visits per
individual most AusPAR online users are from Australia, there is
also substantial international interest, particularly from the USA
and China (Figure S6 in the supplementary data).
Even though most published AusPARs have been for antineo-
plastic and immunomodulating agents (n = 110; 23%) (Figure S7
in the supplementary data), the most viewed AusPARs are for
nervous system drugs (28.0% of the top 25 AusPARs viewed; Figure
S8 in the supplementary data). Medicines for cardiovascular dis-
eases, which were eight of the top ten most prescribed drugs in
Australia for 2012–2013 [20], ranked second for views (17.6%). As
far as application types are concerned, AusPARs for new chemical
and biological entities were the most viewed (38.4% of the top 25
AusPARs; Figure S9 in the supplementary data). There was no
distinct difference in web traffic according to decision outcome
(data not shown). Table S4 in the supplementary data shows thePercentage of visits to AusPAR pages
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Visits to individual document types on Australian Public Assessment Reports (AusPARs) web pages per quarter (July 2013 to December 2014).
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2010–2014.
The web traffic of individual medicines documents over time
showed that most AusPARs produce an initial spike in web traffic
soon after publication (Figure S10 in the supplementary data). A
listing of the medicine on the Pharmaceutical Benefits Scheme
(PBS), by which the Australian Government provides subsidised
prescription drugs to all Australian residents [21], could also pro-
duce a second spike in web traffic. For certain documents, web
traffic was cyclical, such as spikes for influenza vaccines during the
influenza season (Figure S10 in the supplementary data).
Discussion of shared experience
Comparing TGA and EMA practices on public assessment reports,
we see a high degree of similarity in terms of content. Even though
the precise scopes of publication differ, both regulators publish
comprehensive information on their respective assessments. Pub-
lished information presents the basis for the decision of each
authority, together with more detailed supportive data (e.g., clini-
cal trials or PI documents). More significant differences are ob-
served in the process and publication formats. Whereas TGA
publishes an AusPAR for each assessment, EMA brings together
all medicines information in a single location, the EPAR webpage.
EMA publishes the report as adopted by its Committee at the time
of opinion, which is later complemented with a short public
summary. By contrast, TGA prepares an AusPAR after a decision
has been made and attaches the Extract CER document. Although
a detailed comparison with other authorities is beyond the scope
of this paper, many regulators now publish extensive information
on the assessment of medicines; for example, in the USA through
the Drugs@FDA database (www.accessdata.fda.gov/scripts/cder/
drugsatfda) or in Canada with the publication of ‘Summary Basis
of Decision’ (SBDs; www.hc-sc.gc.ca/dhp-mps/prodpharma/
sbd-smd/index-eng.php). Overall, it is clear that regulators sharethe same objectives of transparency and the provision of up-to-
date information even though there are differences in the format
and structure of published information.
Web statistics indicate a high interest in EPARs and AusPARs.
EPAR webpages are the most viewed on the EMA website, while the
AusPAR readership has consistently grown over time. Monitoring
of web statistics provides an insight into audiences’ preferences.
For example, although TGA initially believed that readers would
increasingly start accessing AusPARs at the expense of Extract
CERs, the data have shown the opposite, with Extract CER reader-
ship gradually increasing over time. This underscores the impor-
tance of maintaining a high level of transparency on clinical data
in the assessment report alongside the publication of clinical trials
data in separate databases by EMA. In the interests of public health,
the TGA and EMA are mindful of timely publication of AusPARs
and EPARs, respectively.
The degree of openness represented by the publication of public
assessment reports was a major pioneering step for the two regula-
tory bodies. Increasing publication has served as an ‘internal audit’,
raising the bar for the quality and readability of assessment reports
over time. Publication has evolved with the needs of the various
audiences, from the addition of a short public summary (EPARs) to
the separate publication of the Extract CER (AusPARs). Publication
of EPARs and AusPARs require resources (including for quality
assurance) but facilitates answering requests for information or
access to documents (Figure S11 in the supplementary data). Today,
about a quarter of requests for information to EMA from healthcare
professionals and patients resulted in reference to EPARs, while
about one-third of requests to TGA were directed to AusPARs.
EMA and TGA regularly consult one another and share infor-
mation related to establishing the safety, quality, and efficacy of
new medicines. Ongoing communication between regulators will
allow for the sharing of ideas and continued evolution of public
assessment reports.www.drugdiscoverytoday.com 1811
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Transparency is a fundamental value in developed societies and is
regarded globally as a key feature of a sound national regulatory
system. Patients and healthcare professionals have a right to know
about the scientific basis for the approval and use of their med-
icines [1]. Publication of assessment reports by regulators ensures
transparency in communicating the scientific rationale about the
regulatory decision-making process. Beyond the conclusion of the
regulator, public assessment reports describe the data submitted to
support the request for marketing authorisation and the discus-
sions during assessment; for example, regarding data limitations,
uncertainties, or different views of parties involved in the evalua-
tion. Both EPARs and AusPARs provide up-to-date information on
medicines in line with the latest recommendations for safe and
effective use as presented in the PI. The value of providing accu-
rate, evidence-based information on medicines is enhanced in the
context of a large amount of unreliable or at least nonvalidated
information available, particularly on the internet [22].
The full impact and readership of EPARs and AusPARs by target
audiences is not currently known. However, transparency in the
assessment of applications assists industry in the requirements and
procedures of the regulatory process. Public assessment reports
also provide information that might be relevant to support the
relative effectiveness of a medicine compared with alternative
therapy, or information on available experience in specific sub-
populations. It might also make it easier for stakeholders to review
data from previous trials or compare data from different trials as
part of their research [23]. Public assessment reports can help
readers understand the rationale for divergent outcomes by re-
gional competent authorities.
Rapid scientific progress over the past 10 years has led to an
increase in both the quantity and complexity of the information
that medicine regulators communicate. Along with stakeholders’
desire for greater transparency, the quantity of information con-
tained in each public assessment report and the number of associ-
ated documents have increased over time. A significant challenge
for EMA and TGA is to address these diverse stakeholder require-
ments. Both EPARs and AusPARs represent an important tool for
communicating valuable medicines information; however, given
that multiple stakeholders have diverse needs, it is acknowledged
that one tool might not suit all [24]. For example, healthcare
professionals are likely to have needs and expectations that need
to be supported by a variety of information: either concise, tar-
geted information addressing specific points in clinical practice, or
detailed information to learn about available evidence and possi-
bly stimulate further research. Patients are also becoming more
engaged and knowledgeable about treatment decisions, which
gives rise to a greater demand for reliable information.
Continuing to gather more extensive feedback on the value of
published information is an important objective for both regulators.1812 www.drugdiscoverytoday.comThere is obvious value in involving stakeholders to obtain their
perspectives and tailor communication tools appropriately. At the
time of writing this paper, TGA were undertaking a comprehensive
survey to obtain such feedback from AusPAR readers. Preliminary
findings show that 79% of respondents feel that AusPAR documents
provide transparency in the TGA’s decision-making process either
very well (39%) or well (40%), while 84% feel that AusPAR docu-
ments are either very useful (36%) or useful (48%) for their needs.
Similarly, EMA continues to assess how to best communicate high-
quality information throughout of the lifecycle of a medicine.
Another key project in the EU potentially impacting the future
of EPARs will be the development of the EU Medicines Web Portal,
which aims to create a multi-lingual website giving access to infor-
mation on authorised medicines, irrespective of the EU licensing
route [25].
EMA is committed to continuously extending its approach to
transparency. A key goal in this process is the future publication of
clinical trials data for medicines [26]. This higher degree of transpar-
ency will benefit public health by allowing medicine developers to
learn from past successes and failures or enable the wider scientific
community to make use of detailed clinical data to develop new
knowledge. It might also allow third parties to verify original analy-
sis and conclusions, to conduct further analyses, and to examine the
positions of the regulator and challenge them where appropriate.
TGA does not currently plan to publish clinical trials information.
At a time when even more detailed scientific information is
becoming available, continued dialogue between medicines reg-
ulators and their audiences is essential. Regulators’ efforts in terms
of publication of information on medicines should be driven
towards accessibility and usability by stakeholders. This could
be the opportunity to address the challenge of providing the most
relevant information on medicines at the levels of detail appropri-
ate to the needs of stakeholders.
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